Trial · NCT07074379
Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis
NCT07074379, Not applicable, Recruiting, Changhai Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis. Trials, record NCT07074379. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07074379
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis
- NCT number
- NCT07074379
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 126 participants, estimated
- Lead sponsor
- Changhai Hospital
- Conditions
- Painless Chronic Pancreatitis
- Interventions
Lifestyle modifications, Pancreatic enzyme replacement therapy (PERT) and glycemic control therapy, Endoscopic Retrograde Cholangiopancreatography (ERCP) and/or Extracorporeal Shockwave Lithotripsy (ESWL)
- First posted
- 2025-07-20
- Last updated
- 2026-09-23
Source ClinicalTrials.gov
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Acute Pancreatitis Incidence | 12 months | The incidence of acute pancreatitis assessed by Revised Atlanta Classification over a 12-month period following randomization. |
| Secondary | Severity of Acute Pancreatitis | 12 months | The severity of acute pancreatitis episodes that occur within 12 months post randomization. Severity will be graded according to the Atlanta Classification criteria, which categorizes pancreatitis into mild, moderate, and severe based on clinical and imaging findings. |
| Secondary | Incidence and Severity of Pancreatic Pain | 12 months | The incidence and severity of pancreatic pain over a 12-month period. Pain severity will be measured using the Visual Analogue Scale (VAS), where patients rate their pain on a scale from 0 (no pain) to 10 (worst possible pain). |
| Secondary | Number of Acute Pancreatitis Episodes | 12 months | |
| Secondary | Number of pancreatic pain episodes | 12 months | |
| Secondary | Fecal Elastase-1 Level | 12 months | This outcome assesses pancreatic exocrine function by measuring fecal elastase-1 (FE-1) levels |
| Secondary | Glycosylated Hemoglobin Level | 12 months | This outcome measure evaluates the percentage of hemoglobin that is glycosylated, reflecting the average blood glucose levels over the past 2 to 3 months. It is a key indicator of long-term glycose level in patients. |
| Secondary | Fasting Blood Glucose Level | 12 months | This outcome measure assesses the level of glucose in the blood after an overnight fast. Fasting glucose is a standard test for diagnosing diabetes and monitoring diabetes control. It provides a snapshot of the body's ability to manage glucose without the influence of food. |
| Secondary | Fasting C-Peptide Concentration | 12 months | This outcome measure determines the concentration of C-peptide in the blood during a fasting state. C-peptide is a byproduct of insulin production and provides an index of endogenous insulin secretion. It is useful for assessing insulin production capacity. |
| Secondary | Fasting Insulin Concentration | 12 months |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07074379
GET https://conductscience.org/api/trials/v1/NCT07074379/registered?page=2